Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea

NEXT STORY
TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award
PREV STORY
Global Smart Surfaces Market Research Report 2021: Self-Healing, Self-Sensing and Self-Cleaning Materials Poised to Transform Construction Sector
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The Lupus Initiative Launches National Program to Develop Transformative Care Model; Embarks On Initiative with Collaborative Partners to Expand Lupus Health Care Access to Underserved Populations

The ACR's The Lupus Initiative offers sorely needed education to health providers, while improving ...

author_avatar
NASDAQ Market News

NEOVACS : HALF-YEAR 2018 FINANCIAL RESULTS

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE HALF-YEAR 2018 FINANCIAL RESULTS STRENGTHENED CASH ...

author_avatar
NASDAQ Market News

Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole

Summit Therapeutics plc ("Summit" or the "Company") SUMMIT ENTERS INTO LICENCE AND COMMERCIALISATION AGREEMENT ...

author_avatar
NASDAQ Market News